These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16670362)

  • 1. Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine.
    Ann Pharmacother; 2006 May; 40(5):1007. PubMed ID: 16670362
    [No Abstract]   [Full Text] [Related]  

  • 2. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Apr; 55(13):364-6. PubMed ID: 16601664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1120-4. PubMed ID: 17060898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(40):1023-5. PubMed ID: 16224452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
    Cho BH; Clark TA; Messonnier NE; Ortega-Sanchez IR; Weintraub E; Messonnier ML
    Vaccine; 2010 Jan; 28(3):817-22. PubMed ID: 19879992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alert on meningococcal vaccine.
    FDA Consum; 2005; 39(6):6. PubMed ID: 16669110
    [No Abstract]   [Full Text] [Related]  

  • 8. Current safety issues with quadrivalent meningococcal conjugate vaccines.
    Myers TR; McNeil MM
    Hum Vaccin Immunother; 2018 May; 14(5):1175-1178. PubMed ID: 28934061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.
    De Wals P; Deceuninck G; Boucher RM; Ouakki M
    Clin Infect Dis; 2008 Apr; 46(8):e75-7. PubMed ID: 18444843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guillain-Barré syndrome to meningococcal conjugate vaccine: Menveo
    Moukafih B; Lachhab Z; Moutaouakkil Y; Fettah H; Ahizoune A; Tadlaoui Y; Bennana A; Lamsaouri J; Bousliman Y
    Therapie; 2019 Sep; 74(4):495-498. PubMed ID: 30661720
    [No Abstract]   [Full Text] [Related]  

  • 11. Global Advisory Committee on Vaccine Safety, 12-13 June 2007.
    Wkly Epidemiol Rec; 2007 Jul; 82(28-29):252-9. PubMed ID: 17642098
    [No Abstract]   [Full Text] [Related]  

  • 12. Global Advisory Committee on Vaccine Safety, 29-30 November 2006.
    Wkly Epidemiol Rec; 2007 Jan; 82(3):18-24. PubMed ID: 17236262
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination.
    Velentgas P; Amato AA; Bohn RL; Chan KA; Cochrane T; Funch DP; Dashevsky I; Duddy AL; Gladowski P; Greenberg SA; Kramer JM; McMahill-Walraven C; Nakasato C; Spettell CM; Syat BL; Wahl PM; Walker AM; Zhang F; Brown JS; Platt R
    Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1350-8. PubMed ID: 22807266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2009 Apr; 35(ACS-3):1-40. PubMed ID: 19400026
    [No Abstract]   [Full Text] [Related]  

  • 15. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.
    Velentgas P; Bohn RL; Brown JS; Chan KA; Gladowski P; Holick CN; Kramer JM; Nakasato C; Spettell CM; Walker AM; Zhang F; Platt R
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1226-34. PubMed ID: 18956428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menactra: a meningococcal conjugate vaccine.
    Med Lett Drugs Ther; 2005 Apr; 47(1206):29-31. PubMed ID: 15821633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome and immunizations.
    Randall DP
    Dis Mon; 2010 May; 56(5):293-8. PubMed ID: 20493307
    [No Abstract]   [Full Text] [Related]  

  • 18. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 May; 33(ACS-3):1-23. PubMed ID: 17520774
    [No Abstract]   [Full Text] [Related]  

  • 19. Neisseria meningitidis: epidemiology, treatment and prevention in adolescents.
    Brigham KS; Sandora TJ
    Curr Opin Pediatr; 2009 Aug; 21(4):437-43. PubMed ID: 19421058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythema multiforme after meningitis vaccine: patient safety concerns with repeat immunization.
    Studdiford J; Oppenheim L; McCann E; Altshuler M
    Pharmacotherapy; 2006 Nov; 26(11):1658-61. PubMed ID: 17064213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.